ZNRF3 Genomic Analysis for Prostate Cancer Relapse Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating prostate cancer are inadequate, as they rely on weak surrogates for disease-specific mortality and have a high false discovery rate, failing to accurately predict relapse and metastasis, particularly for aggressive forms of the disease.
Innovation Solution
The use of genomic analysis to identify ZNRF3 genomic loss, reduced expression, and increased methylation in prostate cancer samples, which serves as a prognostic indicator for metastatic relapse and overall survival, informing treatment decisions with aggressive therapies like radiotherapy and hormone therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current risk-stratification guidelines are used (based on Gleason grade, PSA, and T category), then the diagnostic method is simple and widely applicable, but the accuracy in predicting relapse and metastasis is insufficient
Solution Approach 1:
The patent segments the diagnostic approach by introducing a multi-tiered system: first using conventional clinical parameters (Gleason grade, PSA, T category) for initial risk stratification, then applying genomic analysis (mutation panels, expression profiles, methylation patterns) to specific risk groups. This segmentation allows the complex genomic testing to be applied selectively rather than universally, improving predictive accuracy while managing complexity through staged implementation.
Solution Approach 2:
The patent transforms the diagnostic parameters from purely clinical observations to include molecular biomarkers. By measuring genomic mutations, gene expression levels, and epigenetic modifications, the system adds new dimensions of information that directly correlate with metastatic potential and treatment response, thereby enhancing prediction accuracy beyond traditional clinical parameters.
2Reliability
If genome-wide analysis is performed to discover biomarkers, then the approach is unbiased and comprehensive, but the false discovery rate increases due to simultaneous testing of multiple mutations
Solution Approach 1:
The patent extracts specific high-value genomic signals from the noisy background of genome-wide data. Rather than interpreting all mutations simultaneously, the method identifies and isolates specific mutation patterns, gene expression signatures, and epigenetic markers that have been pre-validated or show strong statistical association with metastatic outcomes. This extraction approach maintains the comprehensiveness of genome-wide analysis while reducing false discoveries by focusing on validated biomarkers.
Solution Approach 2:
The patent incorporates feedback mechanisms through validation cohorts and iterative biomarker refinement. Initial biomarker discovery is followed by validation in independent patient cohorts, and the system continuously refines the biomarker panel based on observed performance. This feedback loop allows the system to distinguish true biomarkers from false positives by testing whether identified markers consistently predict outcomes across different patient populations.
3Reliability
If aggressive therapy is administered to all prostate cancer patients, then the treatment intensity is sufficient to prevent relapse, but the treatment intensity causes unnecessary harm to low-risk patients
Solution Approach 1:
The patent applies local quality by tailoring treatment intensity to the specific molecular characteristics of each patient's tumor. Rather than uniform aggressive therapy, the system identifies patients with high-risk genomic profiles (specific mutations, expression patterns, methylation signatures) who would benefit from intensified treatment, while allowing low-risk patients to receive less intensive management. This localized approach matches treatment intensity to actual disease aggressiveness at the molecular level.
Solution Approach 2:
The patent performs preliminary genomic characterization of the tumor before determining treatment intensity. By analyzing mutation status, gene expression profiles, and epigenetic markers at the time of diagnosis, the system predicts which patients are likely to benefit from aggressive therapy versus those who would be harmed by it. This preliminary molecular assessment guides treatment decisions before therapy is administered, preventing unnecessary aggressive treatment in low-risk patients.
Data Source
AI summary
Disclosed herein are methods and compositions for treatment, prognosis, and diagnosis of cancer, including prostate cancer. Aspects of the disclosure are directed to methods for a subject having prostate cancer determined to have ZNRF3 genomic loss, reduced ZNRF3 expression, and/or increased ZNRF3 methylation. Also disclosed are methods for analysis of tumor DNA for ZNRF3 copy number status, expression, and/or methylation, as well as compositions and kits useful for such analysis.